Skip to main content
Caplight Logo









BioReperia

BioReperia

Private
LinköpingHealthcare & Life Scienceshttps://bioreperia.com/

Last Round

Grant

Apr 13, 2021

Total Funding Raised

$1.7M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

BioReperia is a biotechnology company that provides a zebrafish tumor xenograft (ZTX®) platform used to accelerate drug discovery and predict the efficacy of cancer treatments for personalized medicine.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

contract research organizationCROzebrafish tumor xenograftcancer drug discoverypersonalized medicineprecision oncologyzebrafish modelpatient avatarZTX platformin-vivo testingtumor efficacy testingpreclinical drug discoveryclinical decision supportmetastasis analysispatient-derived xenograftPDX modelsimmune oncology modelingtoxicology services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioReperia Comparables

Compare BioReperia with similar companies based on industry and business-model similarity.

BioReperia comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ZeClinics
84%
Hunter Biotechnology
78%
Zefit
77%

BioReperia Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 13, 2021
Series AJul 1, 2019

Key People

Founding team and executive leadership

Anna Erkstam

Chief Executive Officer

Executive Team

Lasse Jensen

Chief Technology Officer

Executive Team

BioReperia Investors

Notable investors and investment history

BioReperia investors
InvestorRounds
LiU InvestSeed
Almi Invest ABSeries A
SwelifeGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 43% MoM.

  • Jun 22, 2026

    Monthly visitors increased 49% MoM.

Recent news

Latest coverage and updates

  • partners_withAug 12, 2026

    BioReperia partnered with Telomir Pharmaceuticals, Inc. on Apr 1st '26.

BioReperia Filings

Explore SEC and related filing metadata, where available.

BioReperia filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BioReperia's valuation, stock price, and market status.

Is BioReperia a public or private company?

BioReperia is a private company.

What is the current stock price of BioReperia?

BioReperia is a private company with no public stock price. No recent secondary market data is available.

How much is BioReperia worth (valuation)?

Valuation information for BioReperia is not publicly available.

Can I buy BioReperia stock?

BioReperia shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BioReperia's last funding round?

BioReperia's most recent funding round was Grant on April 13, 2021.

Who are the main investors in BioReperia?

Key investors in BioReperia include Almi Invest AB.

Will BioReperia IPO soon?

No public IPO plans have been announced for BioReperia.

How can I track BioReperia secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BioReperia's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLinköping
Employee Range17
Year Founded2015
Last FundingApr 13, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?